Thursday, February 16, 2017

Gainers & Losers Of The Day: CRSP, XTLB, CRSP, ACUR, EVOK...

Neuralstem Inc.'s phase 2 trial of NSI-189 for the treatment of major depressive disorder has been completed ahead of schedule.

from RTT - Biotech http://ift.tt/2kYVrrs
via IFTTT
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)